Clinical trials: Alcohol Use Disorder, Severe
Depressive Disorder, Major, Alcoholism
Vortioxetine for Treatment of Depressive Mood and Alcohol Use
This is a randomized, double-blinded, placebo-controlled, multicenter study. A total of 128 subjects will be randomly assigned to a test group or placebo group in a 1:1 ratio.
- Trial name
- NCT04498897
- Testing
- Vortioxetine, Acamprosate
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Hanyang University Seoul Hospital
Alcohol Use Disorder
Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects
Double-blind randomised, parallel-group, three-arm, multicentre, placebo-controlled study The primary objective is to demonstrate the superiority of the combination of Periactine® (cyproheptadine 8 mg/day or 12 mg/day) and…
- Trial name
- COCKTAIL (NCT04108104)
- Testing
- Cyproheptadine, Alpress LP
- Where
- 35 sites in France
- Volunteers
- 154 people
- Sponsor
- Kinnov Therapeutics
Substance Use, Severe Mental Disorder
Validation of the Dutch Translation of the Tobacco, Alcohol, Prescription Medication and Other Substances (TAPS)-Tool
The aim of the study is to investigate the reliability and validity of the Dutch version of the TAPS-tool. This will be investigated in 2 groups: patients without intellectual disabilities treated in Flexible Assertive Community…
- Conditions
- Substance Use, Severe Mental Disorder, Intellectual Disability, Mild
- Trial name
- NCT05273021
- Testing
- TAPS
- Where
- 3 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Birgit Seelen-de Lang
Severe Alcoholic Hepatitis
LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis
Background \& Rationale Severe alcohol-related hepatitis (SAH) is a serious condition with a 3-month mortality rate of ~30%. Diagnosis and prognosis are complex due to non-specific and insensitive clinical, biological, and…
- Trial name
- Liver TREM-1 (NCT07176741)
- Testing
- TREM-1 expression (via immunohistochemistry) between SAH patients and controls
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)
To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.
- Conditions
- Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD), Comorbidities and Coexisting Conditions
- Trial name
- KET-DUAL (NCT07247370)
- Testing
- Ketamine, Cognitive Behavioural Therapy
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- South West Sydney Local Health District
Major Depressive Disorder, Alcohol Use Disorder
Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
The investigators will compare 3 treatment groups (ketamine plus naltrexone vs. ketamine alone vs. placebo) for treating major depressive disorder (MDD) and alcohol use disorder (AUD) in an 8-week randomized, double-blind…
- Trial name
- NCT02461927
- Testing
- Ketamine + Naltrexone
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- VA Office of Research and Development
Alcohol-associated Hepatitis
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
- Trial name
- ITAALD (NCT07060638)
- Testing
- IL-22, Prednisone, Acamprosate
- Where
- 6 sites in United States
- Volunteers
- 216 people
- Sponsor
- Samer Gawrieh
OCD, Major Depressive Disorder (MDD)
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic…
- Conditions
- OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer
- Trial name
- NCT06624137
- Testing
- Serotonergic Psychedelic
- Where
- 2 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Yale University
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder
This study will evaluate whether pregnenolone is an effective treatment for adults with Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD).
- Trial name
- PREG-AUD-RO1 (NCT07734701)
- Testing
- Pregnenolone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sherwood Brown, MD, PhD
Major Depressive Disorder, Alcohol Use Disorder
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Recent reports have shown that alcohol misuse is a particularly serious problem among the 18 to 25 year old age group. Previous medication trials with SSRI antidepressants among young adults with co-occurring depressive…
- Trial name
- YAAD-P (NCT02646449)
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Severe Alcoholic Hepatitis
Rifaximin Use in Severe Alcoholic Hepatitis
This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.
- Trial name
- NCT02485106
- Testing
- Rifaximin, Corticosteroid or pentoxifylline
- Volunteers
- 170 people
- Sponsor
- Saint Vincent's Hospital, Korea
Addiction, Alcohol
Impact of a Brief Motivational Intervention Including Counter-marketing Arguments With a Population of Patients With Moderate to Severe Alcohol Use Disorders Who Are Followed up on an Outpatient Basis (Primary Care or Addictology) (DEPREV_Phase 3)
Alcohol consumption is the second cause of avoidable death after tobacco. The Evin law was constructed in 1991 with the aim of reducing exposure to alcohol marketing among the youngest.
- Trial name
- NCT04881500
- Testing
- Motivational interview, Routine Care
- Where
- 6 sites in France
- Volunteers
- 83 people
- Sponsor
- University Hospital, Brest
Alcohol Use Disorder
Social Cognition in Severe Alcohol Use Disorder
With 41,000 deaths per year, alcohol consumption is the second leading cause of preventable mortality in France. Nearly 3.4% of adults engage in excessive and chronic alcohol use, meeting criteria for Severe Alcohol Use Disorder…
- Trial name
- COSMO (NCT07464613)
- Testing
- Analysis of social functioning and social cognition processes
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
- Trial name
- NCT06160232
- Testing
- Psilocybin (high dose)
- Where
- Belgium
- Volunteers
- 62 people
- Sponsor
- Brugmann University Hospital
Alcohol Dependence, Major Depression
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
STUDY OBJECTIVES: The primary objective of this study is to compare the safety and efficacy of acamprosate versus placebo in the treatment of alcohol dependence in adults with co-occurring mood or anxiety disorders (specifically…
- Conditions
- Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
- Trial name
- NCT00330174
- Testing
- Acamprosate
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder, Alcohol Use Disorder
STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
The purpose of this study is to determine if having an alcohol use disorder affects recovery from depression, and also whether recovery from depression in patients who have alcohol use disorders is also accompanied by improvement…
- Trial name
- NCT00369746
- Testing
- citalopram
- Where
- United States
- Volunteers
- 674 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Alcohol Use Disorder
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol…
- Trial name
- PsiloMDDAUD (NCT04620759)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Alcohol Use Disorder
Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
- Trial name
- NCT06545916
- Testing
- Sunobinop
- Where
- 7 sites in United States, Romania
- Volunteers
- 209 people
- Sponsor
- Knoa Pharma LLC
Substance Abuse, Substance Dependence
Group Therapy for Women Prisoners With Comorbid Substance Use and Depression
The purpose of the study is to determine whether interpersonal psychotherapy is effective for treating co-occurring depression and substance use among women prisoners.
- Conditions
- Substance Abuse, Substance Dependence, Depressive Disorder
- Trial name
- NCT00606996
- Testing
- Group interpersonal psychotherapy (IPT-G), Psychoeducation on co-occurring disorders (PSYCHOED)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Brown University
Alcohol Use Disorder
Deep Brain Stimulation for Alcohol Use Disorder
The purpose of this clinical study is to investigate the safety, tolerability, and feasibility of Deep Brain Stimulation (DBS) of the limbic pallidum in participants with severe alcohol use disorder (AUD) who have advanced but…
- Trial name
- NCT05522751
- Testing
- DBS
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Khaled Moussawi